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Safety of adjuvant endocrine 
therapies in hormone receptor– 
positive early breast cancer
tissues such as bone 2. The a is, on the other hand, 
block the ability of the aromatase enzyme to convert 
androgen precursors in peripheral tissues to estrogen, 
which is the major source of circulating estrogen in 
postmenopausal women 3. Both classes of agents 
result in accelerated symptoms of estrogen deple-
tion, which has an effect on bone, cardiovascular, 
and gynecologic health and which can also give rise 
to arthralgia. However, because of their differing 
modes of action, the s e r ms and a is have different 
side-effect profiles.
The effects of tamoxifen are well documented 
and include gynecologic symptoms, an increased risk 
of endometrial cancer, and an increased risk of deep-
vein thrombosis 4. The a is, because of their profound 
ability to deplete estrogen, are associated in clinical 
trials with loss of bone density, musculoskeletal pain, 
and arthralgia 5. Although the choice of adjuvant 
agent depends on patient characteristics such as age, 
comorbidities, and so on, the a is are increasingly 
becoming first-line agents based on their efficacy 
and tolerability profiles. However, it is important 
for clinicians to be aware of the differential toxicity 
profiles of these agents as compared with tamoxifen 
and to be familiar with various strategies for manag-
ing the potential side effects. It is also important to 
consider how toxicity data were obtained, because 
these data often vary from study to study and may 
result in misleading interpretations.
For example, to prevent potential bias in event 
reporting in the Arimidex, Tamoxifen, Alone or in 
Combination (a t a c) trial, the largest and longest trial 
evaluating an a i , investigators were required to ask 
patients at every visit whether they had suffered ad-
verse effects rather to use pre-specified checklists 6. 
On the other hand, the Breast International Group 
(b i g) 1-98 trial comparing letrozole with tamoxifen 
reported adverse events by checking specific boxes 
on case report forms 7. A decision to specifically 
record particular events may yield conclusions that 
are different from those resulting from nonspecific 
reporting of adverse effects, and advocates of the 
former approach may argue that “if you do not look, 
you may not find” 8.
ABSTRACT
Postmenopausal patients with hormone-sensitive 
early breast cancer are typically treated with adjuvant 
endocrine therapy, which significantly reduces the risk 
of recurrence. Because treatment is of a long duration, 
side effects from adjuvant therapy can be problematic. 
The aromatase inhibitors (a i s) are replacing tamoxifen 
as first-line treatment agents for early breast cancer. 
Here, we present the side-effect data associated with 
a i s in relation to bone, gynecologic, and cardiovascu-
lar health and to arthralgia and myalgia. Although a i s 
have been shown to decrease bone density, increase 
arthralgia, and affect vaginal health, these adverse 
events are usually manageable, and several strategies 
can be followed to improve quality of life in women 
on a i  treatment. To optimize adherence to therapy. It 
is important that these issues are addressed so that 
women can benefit from treatment.
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1.  INTRODUCTION
The selective estrogen receptor (s e r m) antagonist 
tamoxifen and, more recently, the aromatase inhibi-
tors (a is) anastrozole, exemestane, and letrozole have 
all been used as adjuvant endocrine therapy agents 
for the treatment of hormone receptor–positive early 
breast cancer. Because the presence of circulating 
estrogen is associated with breast cancer recurrence 1, 
these therapies are targeted toward reducing or ab-
rogating circulating estrogen.
Long-term treatment with endocrine agents 
raises issues both for patients and for physicians in 
balancing the potential benefits of reducing recur-
rence with the possible side effects. The s e r ms and 
a is reduce estrogen in different ways. The s e r ms bind 
to the estrogen receptor on tumour cells, thus block-
ing the ability of the cells to proliferate; however, 
the s e r ms also have estrogenic effects on certain 
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2.  BONE HEALTH
2.1  Background
Typically, bone health may deteriorate in menopausal 
women, because a decline in estrogen concentration 
accelerates bone loss 9,10, and women with breast 
cancer are at added risk. The Women’s Health Initia-
tive Observational Study showed that bone mineral 
density (b m d) is lower in breast cancer survivors than 
in matched controls and that osteoporosis is often 
undiagnosed in these women 11. A recent study also 
showed that after 29.5 months, lumbar b m d  is lower 
in women who have undergone chemotherapy 12.
Not surprisingly, given the profound estrogen de-
pletion effect of a is, clinical trials have demonstrated 
an increased risk of fractures with a i treatment as 
compared with treatment with tamoxifen (Table i). In 
those trials, women on anastrozole 6,14,15,18, letrozole 7 
or exemestane 17 were all found to have a higher in-
cidence of fracture than were women on tamoxifen, 
and the incidence varied with the a i and the time 
to analysis. In contrast, tamoxifen has been associ-
ated with increased b m d  in postmenopausal women 
treated for breast cancer, but with decreased b m d  in 
premenopausal women 19.
The a t a c  trial included a bone subprotocol 
involving 81 and 86 women on anastrozole and ta-
moxifen monotherapy respectively, who either had 
normal b m d  or osteopenia at baseline. At 5 years, no 
women with normal b m d  on either treatment became 
osteoporotic, but anastrozole was associated with 
a statistically significant (p = 0.0001) decrease in 
hip and lumbar spine b m d  20. As well, turnover of 
the bone markers N-terminal telopeptide of type 1 
collagen and bone alkaline phosphatase was higher 
and b m d  was lower after 1 year of anastrozole 
treatment as compared with 1 year of tamoxifen 
treatment 21,22. Similar results have been reported 
for letrozole.
The National Cancer Institute of Canada Clini-
cal Trials Group study m a .17B evaluated bone turn-
over markers and b m d  in postmenopausal women 
randomly assigned to letrozole or placebo after 
standard adjuvant tamoxifen 23. At 24 months, pa-
tients receiving letrozole experienced significant 
decreases in both total hip and lumbar spine b m d . 
Similarly, women switched to exemestane following 
tamoxifen for 2–3 years showed a marked increase 
in bone turnover markers with a decrease in b m d  24. 
A substudy of the German Tamoxifen Exemestane 
Adjuvant Multinational trial also recently showed a 
decrease in b m d  at the spine in women on exemestane; 
tamoxifen had a protective effect 25.
In healthy postmenopausal women, a is also de-
crease estrogen and increase bone markers, as demon-
strated in the Letrozole, Exemestane and Anastrozole 
Pharmacodynamic trial. Changes were comparable 
with each a i except for exemestane, which increased 
procollagen type 1 N-terminal propeptide 4 times 
more than did the other a is at 24 weeks 26.
2.2  Recent Evidence
Current thinking is that the benefits of a i treatment 
outweigh the risks of bone fracture, because osteo-
porotic therapy can be simultaneously given and 
has recently been shown to be highly effective. In 
the Study of Anastrozole with the Bisphosphonate 
Risedronate (s a b r e), 234 women on anastrozole con-
currently treated with the bisphosphonate risedronate 
showed an increase in b m d  and a decrease in bone 
turnover markers at 12 months as compared with 
results in women on anastrozole alone 27. Similarly, in 
another double-blind randomized placebo-controlled 
study to evaluate the effect of a bisphosphonate in 
women on anastrozole (the a r i b o n  trial), monthly 
ibandronate was associated with bone loss prevention 
and increases in b m d  at the lumbar spine and hip in 
osteopenic and osteoporotic patients at 2 years 28.
t a b l e  i  Fracture rates with tamoxifen and aromatase inhibitor treatment
Studya Fracture rates (%) with p Value Comment
Tamoxifen Anastrozole Letrozole Exemestane
a t a c
At 60 months 13 7 11 <0.0001 Age and geographic location
At 100 months 14,15 1.9 2.9 <0.0001    added risk for fracture 16.
Treatment completed 1.51 1.56 0.79
b i g  1-98
At 25.8 months 7 4 5.7 <0.001
At 51 months 8 5.8 8.6 <0.001
i e s  17 2.3 3.1 0.08 Patients switched to exemestane
   after 2–3 years on tamoxifen.
a   Because of differing methodologies, direct comparisons should not be made between the studies.
a t a c  = Arimidex, Tamoxifen, Alone or in Combination; b i g  = Breast International Group; i e s = Intergroup Exemestane Study.SEHDEV et al.
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In the Zometa–Femara Adjuvant Synergy Trial, 
concomitant administration of zoledronic acid in 
522 women started on letrozole (“upfront group”) 
resulted in significantly higher lumbar spine and 
hip b m d  at 24 months than was seen in the 538 
women who were given the bisphosphonate only if 
their T-score fell to –2 or lower during therapy, or if 
spinal fracture was evident at 36 months (8.2% vs. 
4.7% respectively) 29. Predictably, fewer fractures 
occurred in women given zoledronic acid up front 
(2.5% vs. 3.2%). Similarly, a substudy of the Inter-
national Breast Cancer Intervention Study showed 
that, although women on anastrozole experienced 
significant bone loss as compared with losses 
seen in women on placebo, women who joined the 
study with an osteopenic or osteoporotic T score 
gained b m d  after receiving risedronate treatment 
for 1 year 30.
In premenopausal women, treatment with gos-
erelin plus tamoxifen or anastrozole for 3 years 
was associated with significant bone loss, and bone 
was still compromised after 5 years, particularly in 
women who had been on anastrozole. However, 4 mg 
zoledronic acid given every 6 months for 3 years 
completely inhibited bone loss and led to improved 
b m d  at 5 years 31. Similarly, in the 100-month evalu-
ation of the a t a c  trial, though fracture rates overall 
were higher in women on anastrozole during the 
treatment period, the reported fracture incidence 
was the same after treatment had been completed 15; 
a recovery of b m d  was noted at the lumbar spine and 
a slowing in loss at the hip was observed in women 
on anastrozole after completion of treatment 32.
2.3  Management
Bone loss should be a consideration in women on a i 
treatment, and regular screening is recommended. 
The American Society of Clinical Oncology (a s c o) 
recommended in 2003 that all women at high risk 
of osteoporosis, including women on a is, undergo 
baseline assessment of b m d  and annual monitoring 
while on treatment for breast cancer 33. However, a 
suggestion has since been made that regular monitor-
ing be carried out only on patients at risk for osteo-
porosis 34 because, in the a t a c  trial, no women with 
normal b m d  at baseline had developed osteoporosis at 
5 years 13, and b m d  appeared to recover or slow once 
patients stopped treatment 32. Risk factors include an 
age of 60 years or older, cigarette smoking, steroid 
use, family history of osteoporosis, and a low body 
mass index 35. To prevent bone loss, lifestyle changes 
that can improve or maintain bone health, such as in-
creased exercise, should be discussed with the patient 
before the start of a i therapy 36. Data from recent trials 
(as described earlier) indicate that, when necessary, 
bisphosphonate therapy can prevent further bone loss, 
so that patients can continue with a i therapy.
3.  ARTHRALGIA
3.1  Background
Joint and musculoskeletal pain increase with age 
in women, reaching a peak during menopause and 
postmenopause, suggesting that symptoms may be 
related to estrogen depletion 37,38. In clinical trials, 
the a is are associated with a higher incidence of joint 
symptoms than tamoxifen treatment is (Table ii), with 
a variation in incidence with the various a is, likely 
because of different data-gathering methods.
If pain occurs, it seems to manifest shortly af-
ter the initiation of treatment. For example, in the 
a t a c  trial, arthralgia was most common in the first 
6 months after the start of treatment 13. However, for 
most patients in the a t a c  trial, symptoms resolved 
within 18 months of starting treatment, and of the 
patients who recovered, half were symptom-free 
within 6 months of onset 41.
3.2  Recent Evidence
A substudy of the a t a c  trial revealed that risk factors 
for developing joint symptoms were prior use of 
t a b l e  ii  Incidence of arthralgia with tamoxifen and aromatase inhibitor treatment
Study Incidence of arthralgia (%) with p Value Comment
Tamoxifen Anastrozole Letrozole Exemestane
a t a c At 60 months 13 29.4 39.6 0.0001
b i g  1-98 At 51 months 39 13.5 20 <0.001
m a .17 40 21 25 0.001 Women switched to letrozole
   following 5 years of tamoxifen.
     More women experienced myalgia 
than experienced arthritis.
i e s  17 3.6 5.4 0.01 Women switched to exemestane
   following 2–3 years of tamoxifen.
a t a c  = Arimidex, Tamoxifen, Alone or in Combination; b i g  = Breast International Group; i e s = Intergroup Exemestane Study.SAFETY OF ADJUVANT ENDOCRINE THERAPIES
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hormone replacement therapy, hormone receptor posi-
tivity, obesity, prior chemotherapy, and treatment with 
anastrozole, leading to significant symptom increases 
of 12.3%, 8.2%, 6.8%, 5.9%, and 5.7% respectively 42. 
In a small study of 170 women with invasive estrogen 
receptor–positive breast cancer, who were treated with 
either anastrozole for 12 weeks followed by letrozole 
(or the reverse) and who were subsequently switched to 
tamoxifen, joint pain was reported by 76% while on an 
a i , and no difference between the two a is was ob-
served 43. Interestingly, in that study, 50% of the patients 
with joint symptoms on one a i did not have symptoms 
when switched to the other a i , and 75% of the patients 
who had symptoms on an a i did not have symptoms on 
tamoxifen. These data indicate the possibility of switch-
ing a is should joint pain be problematic.
An association between persistent musculoskel-
etal pain and vitamin D hypovitaminosis has been 
reported 44. In a recent study, women with invasive 
breast cancer who were started on letrozole together 
with vitamin D supplementation (50,000 IU weekly) 
showed improvement in joint symptoms and fa-
tigue 45. Interestingly, in that study, 63% of women 
initiating a i therapy had vitamin D insufficiency (less 
than 32 ng/mL).
3.3  Management
The prevalence of arthralgia in patients on a is can 
be significant. In a small study of 56 patients who 
were not in clinical trials but who were receiving a is, 
arthralgia or bone pain or both were reported in 61% 
and resulted in discontinuation of the drug in 20% 46. 
Thus, adequate and prompt management of pain is 
required. Arthralgia associated with a i treatment is 
usually manageable and has been comprehensively 
dealt with by Thorne, with an algorithm for diagnosis 
and treatment (Figure 1) 47. Briefly, the following 
steps are advocated:
Physical examination and patient history are  • 
required to rule out pain from osteoarthritis, rheu-
matoid arthritis, sleep disturbance, and so on.
Articular pain should be distinguished from  • 
nonarticular pain, and inflammatory from non-
inflammatory pain.
The most common sites of arthralgia are the  • 
knees, hands, wrists, and shoulders.
The most appropriate intervention for pain  • 
management may be a combination of lifestyle 
changes—for example, exercise, and calcium 
f i g u r e  1  Management of musculoskeletal symptoms in patients with early breast cancer taking an aromatase inhibitor 47. O t C  = over-the-
counter; C O x -2 = cyclooxygenase 2; n S a i d  = nonsteroidal anti-inflammatory drug; t C a  = tricyclic antidepressant; ia = intra-articular.
†   Misoprostol or proton pump inhibitor.SEHDEV et al.
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and vitamin D supplements—in conjunction with 
pharmacologic interventions.
Drug therapy includes the use of acetaminophen,  • 
nonsteroidal anti-inflammatory drugs, opiates, 
glucosamine, and topical medications such as 
capsaicin or methylsalicylate.
Patients with severe pain should be referred to a  • 
rheumatologist.
Pain from bone metastases should be ruled out  • 
by history and physical examination or, where 
appropriate, imaging studies.
A drug holiday of 3–4 weeks can also be helpful  • 
in confirming the cause of the pain. Anecdot-
ally, rechallenge with the same a i is often well 
tolerated, but if symptoms significantly affect 
quality of life or impair activities of daily 
living, a switch to another endocrine agent can 
be considered.
4.  GYNECOLOGIC HEALTH
4.1  Background
As compared with placebo, tamoxifen treatment is 
associated with an increased incidence of vaginal 
bleeding, endometrial polyps, endometrial thicken-
ing, and ovarian cysts. Prolonged use is associated 
with significant gynecologic complications, includ-
ing a doubled to tripled risk of endometrial cancer 4. 
By comparison, quality-of-life assessments in the 
a t a c  trial reported that, as compared with women 
on tamoxifen, women on anastrozole experienced 
fewer hot flashes, vaginal bleeding, and vaginal dis-
charge 13 (Table iii), but more vaginal dryness, painful 
intercourse, and loss of sexual interest 48. The risk 
of endometrial cancer was in women on anastrozole 
was one quarter that seen in women on tamoxifen 
(0.2% vs. 0.8% respectively) 13.
As compared with women on tamoxifen, women 
on letrozole in the b i g  1-98 study also suffered sig-
nificantly less vaginal bleeding and fewer hot flashes 
(Table iii). However, in the Intergroup Exemestane 
Study (i e s), in which women were switched to ex-
emestane after 2–3 years on tamoxifen, more women 
on exemestane experienced hot flashes; however, the 
difference was not statistically significant 17.
As compared with the 60-month analysis 13, the 
100-month analysis 15 of the a t a c  trial showed no dif-
ference in gynecologic symptoms, except for a higher 
incidence of endometrial cancer with tamoxifen than 
with anastrozole (Table iii)—an incidence that persist-
ed when treatment was completed 15. In the i e s trial, 
analysis of data 5 years post randomization showed 
that hot flushes and night sweats remained prob-
lematic not only for women who had been switched 
to exemestane, but also for those who remained on 
tamoxifen; however, severe vaginal discharge was 
significantly higher for those on tamoxifen 49.
Estrogen levels in women on a i  treatment are so 
low that their response to estrogen may be heightened, 
and the effect of this heightened response on breast 
cancer recurrence is unknown. In a prospective study, 
7 postmenopausal women on a i  treatment who were 
started on a vaginal estrogen tablet for severe symp-
toms of atrophic vaginitis showed significantly raised 
serum estradiol levels within 2 weeks 50. Because 
the efficacy of a i s is based on completely depleting 
estrogen to prevent proliferation of tumour cells, that 
effect might be counteracted with increases in systemic 
estrogen 51. However, in another small study, 5 of 12 
women on a i  treatment concurrently treated with vagi-
nal estrogen for 3 months experienced no increase in 
serum estrogen levels (the remainder did), suggesting 
that a subset of women on a i  therapy may be able to 
use vaginal estrogen to treat vaginal atrophy 52. In the 
absence of a definitive link between topical estrogen 
t a b l e  iii  Incidence of gynecologic symptoms in women on aromatase inhibitors (a i ) or tamoxifen (t a m )
Trial Treatment arm Incidence (%) of






a i t a m a i t a m a i t a m a i t a m
a t a c At 60 months 13 Anastrozole vs. tamoxifen 35.7 40.9 5.4 10.2 3.2 13.2 0.2 0.8
p<0.0001 p<0.0001 p<0.0001 p=0.02
At 100 months 15 Anastrozole vs. tamoxifen n r n r n r n r n r n r 0.03 0.13
b i g  1-98 At 25.8 months 7 Letrozole vs. tamoxifen 33.5 38 3.3 6.6 n r n r 0.1 0.3
p<0.001 p<0.001 p=0.18
At 51 months 39 Letrozole vs. tamoxifen 32.8 37.4 3.8 8.3 n r n r 0.16 0.65
p<0.001 p<0.001 n r
i e s  17 Exemestane following 2–3 years tamoxifen 42 39.6 4 5.5 n r n s
vs. tamoxifen p=0.082 p=0.087
a t a c  = Arimidex, Tamoxifen, Alone or in Combination; n r  = not reported; b i g  = Breast International Group; i e s = Intergroup Exemestane 
Study; n s  = nonsignificant.SAFETY OF ADJUVANT ENDOCRINE THERAPIES
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therapies and breast cancer prognosis, the Society of 
Obstetricians and Gynaecologists of Canada suggest 
that women with a history of breast cancer first consider 
non-hormonal options to treat symptoms of vaginal 
atrophy, but that local intravaginal estrogen may be 
considered for women with low risk of recurrence if 
non-hormonal options are ineffective and quality of 
life becomes an issue 53.
4.2  Management
Lifestyle modifications such as the use of layered 
clothing—or even acupuncture, meditation, and 
biofeedback—have been suggested for alleviating hot 
flashes in women on adjuvant hormone therapy 54. If 
symptoms are severe, selective serotonin reuptake 
inhibitors such as venlafaxine, sertraline, and parox-
etine are recommended 54. As compared with placebo, 
venlafaxine, even at 37.5 mg, can considerably reduce 
hot flashes 55. However, tamoxifen is converted to its 
active metabolite endoxifen by the cytochrome 450 
enzyme CYP2D6 56 and venlafaxine has been found to 
be a weak inhibitor of CYP2D6 (paroxetine is a potent 
inhibitor) 57. Thus, in women who are genetically pre-
disposed to show less-effective CYP2D6 metabolism, 
possible drug interactions should be assessed 58.
Management of sexual dysfunction in postmeno-
pausal women on a i  therapy has recently been re-
viewed by Derzko et al. 59. Briefly, the following steps 
are advocated in women with sexual dysfunction:
A sexual history, physical examination, and hor- • 
monal evaluation should be carried out.
Therapeutic interventions should be tailored to  • 
address each area of distress.
Non-hormonal treatments are the first-line recom- • 
mendation for urogenital atrophy, vaginitis, and 
dyspareunia.
Vaginal dryness may be treated with lubricants. • 
Low-dose local vaginal estrogen therapy may be  • 
considered for highly symptomatic patients who 
are unresponsive to non-hormonal therapy, but 
this approach is controversial.
5.  CARDIOVASCULAR HEALTH
5.1  Background
Mortality in breast cancer survivors occurs not only 
because of cancer recurrence, but also because of 
cardiovascular (c v ) disease (death from other causes 
has not been found to be significantly elevated) 60. 
Thus, it is important to evaluate the c v  effects of 
agents used for adjuvant endocrine treatment, par-
ticularly in women at risk.
In the a t a c  trial, no difference was observed 
in the occurrence of ischemic c v events between 
women on tamoxifen and those on anastrozole, and 
the most common event was angina 6. Alterations in 
lipid profile, such as increases in cholesterol, triglyc-
erides, and low-density lipoprotein (l d l) cholesterol, 
and decreases in high-density lipoprotein (h d l) 
cholesterol are risk factors for the development of c v 
disease. Tamoxifen has been shown to decrease l d l  
by 20% and total cholesterol by 12% in disease-free 
postmenopausal women after 2 years, with the ef-
fect being maintained after 5 years of treatment 61,62. 
Similar effects were found in postmenopausal node-
negative breast cancer patients on tamoxifen 63. The 
a is, on the other hand, have shown varying effects 
on serum lipid levels. Some studies show anastrozole 
having little effect on serum lipids; others show hy-
percholesterolemia 64. Although lipid concentrations 
were not routinely assessed in the a t a c  trial, women 
on anastrozole showed a higher incidence of hyper-
cholesterolemia than did those on tamoxifen 6.
A similar situation has held for letrozole: con-
flicting data on lipid levels have been seen. In the 
b i g  1-98 trial, analysis at 51 months showed hyper-
cholesterolemia (predominantly grades 1 and 2) in 
51% of women on letrozole as compared with 25% of 
women on tamoxifen (p < 0.001, Table iv) 39. However 
those data might be misleading, because cholesterol 
levels (non-fasting) were analyzed every 6 months, 
and even a single high reading was reported as an 
event 7. Furthermore, the median changes were not 
substantially different from baseline levels, whereas 
baseline levels declined in women on tamoxifen 7, 
suggesting that the difference between the letrozole 
and the tamoxifen groups may have been more reflec-
tive of the cholesterol-lowering effect of tamoxifen 63. 
Although the overall incidence of cardiac events did 
not vary between the two groups at 51 months, a trend 
toward higher-grade cardiac events was observed 
in women on letrozole 65. A substudy of the m a .17 
trial specifically looking at lipid levels showed that, 
as compared with placebo, letrozole did not signifi-
cantly alter serum cholesterol, h d l  cholesterol, l d l  
cholesterol, or triglycerides in non-hyperlipidemic 
postmenopausal women with primary breast cancer 
treated for up to 36 months after having received at 
least 5 years of adjuvant tamoxifen therapy 66.
Trials of exemestane for advanced breast cancer 
have also yielded conflicting results. One study 
showed a reduction in cholesterol and total triglycer-
ides, but also an unfavourable reduction in h d l ; and 
another trial showed no lipid changes 67.
It is important to remember that lipid levels are 
surrogate endpoints and do not necessarily have an 
effect on c v  disease. Despite the favourable effect 
of tamoxifen on lipid profiles, a meta-analysis of 
tamoxifen trials showed no effect on the incidence of 
myocardial infarction (m i ), though death from m i  was 
decreased in women likely to have hyperlipidemia 
and coronary artery disease 68. Also, tamoxifen is 
associated with an increased incidence of stroke and 
an increased risk of venous thromboembolism 68. In 
the a t a c  trial, anastrozole was associated with a lower SEHDEV et al.
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incidence of thromboembolic and cerebrovascular 
events than was tamoxifen 13 (Table iv). Interestingly, 
the Italian Tamoxifen Anastrozole trial showed little 
difference between tamoxifen and anastrozole in 
terms of c v  diseases (6.2% and 7.6% respectively) 
at 64 months 69. A statistically significant (p < 0.001) 
lower incidence of thromboembolic events was ob-
served with letrozole as compared with tamoxifen 
in the b i g 1-98 trial 7,39. However, compared with 
placebo, letrozole showed no statistically significant 
difference in terms of thromboembolic events, m i , 
stroke, or angina. In the i e s trial, in which women were 
switched from tamoxifen to exemestane after 2–3 
years, exemestane was associated with an increase 
in m i  (1% vs. 0.4% with tamoxifen, p = 0.02); how-
ever, this increase was considered to be statistically 
nonsignificant, because the cut-off for significance 
was p = 0.01 17.
5.2  Recent Evidence
The s a b r e  study, which was designed to assess the 
efficacy of concurrent administration of risedronate 
with anastrozole on bone health, also monitored lipid 
levels. After 12 months, l d l  was decreased, h d l  was 
increased, and no change was observed in total cho-
lesterol both in women on anastrozole alone and in 
those concurrently treated with the bisphosphonate 27. 
The 100-month evaluation of the a t a c  trial showed no 
difference in the incidence of m i  between women on 
anastrozole and those on tamoxifen, and a decreased 
incidence of cerebrovascular events with anastrozole 
(Table iv) 15. Similarly, in the 5-year analysis of the b i g  
1-98 trial, although hypercholesterolemia was evident 
in twice as many (51%) women on letrozole as on 
tamoxifen (26%), no difference was observed in car-
diac events between the two groups, and a decreased 
incidence (p < 0.001) of thromboembolic events was 
observed in women on letrozole 70. Furthermore, 
safety data from several major clinical trials were 
recently reviewed to assess c v adverse events among 
the a is, and c v profiles were found to be similar 
among women on a is (as compared with profiles in 
women on tamoxifen) 71. However, it was recognized 
that, because of the lack of long-term data, clinical 
cardiac outcomes and lipid profiles should be closely 
monitored in patients taking an a i.
5.3  Management
No current evidence suggests that the a is have a par-
ticular adverse effect on c v health. As noted in the 
clinical trials, differences in lipid levels, as compared 
with levels in women taking tamoxifen, may have 
more to do with the protective effect of tamoxifen on 
lipid levels than with an adverse effect of the a is 51. 
Patients receiving endocrine treatment should un-
dergo a c v risk assessment and their blood pressure, 
cholesterol levels, and similar parameters should be 
monitored as part of a routine health check; however, 
no specific management strategies are required 51. 
As is the case for healthy individuals, women are 
encouraged to exercise and quit smoking.
6.  CONCLUSIONS
Many of the side effects associated with the a is stem 
from their accelerated effect on estrogen depletion, 
but in general, these agents are well tolerated. So 
far, no current evidence shows that a is might be 
t a b l e  iv  Incidence of cardiovascular and cerebrovascular events in women on aromatase inhibitors (a i s) and tamoxifen (t a m )
Trial Treatment arms Incidence (%) of
Hyperchol- Cardiovascular Cerebrovascular Thromboembolic
esterolemia disease events events
a i t a m a i t a m a i t a m a i t a m
a t a c At 60 months 13 Anastrozole vs. tamoxifen n r n r 4.1 3.4 2.0 2.8 4.5 6.9
p<0.1 p<0.03 p<0.03
At 100 months 15 Anastrozole vs. tamoxifen n r n r 0.27a 0.27a 0.16 0.28 n r n r
b i g  1-98 At 25.8 months 7 Letrozole vs. tamoxifen 43.6 19.2 6.8 5.6 1.0 1.0 1.5 3.5
p=0.91 p<0.001
At 51 months 39 Letrozole vs. tamoxifen 50.6 24.6 9.5 7.5 1.4 1.4 2.0 3.8
p<0.001 p<0.001
i e s  17 Exemestane following 42 39.6 42.6b 39.2b n r n r 1.0 1.9
2–3 years tamoxifen 
   vs. tamoxifen
p=0.082 p=0.016 p=0.005
a   Incidence of myocardial infarction.
b   Not including myocardial infarction.
a t a c  = Arimidex, Tamoxifen, Alone or in Combination; n r  = not reported; b i g  = Breast International Group; i e s = Intergroup Exemestane 
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associated with a serious adverse event such as the 
increased incidence of endometrial cancer noted with 
tamoxifen treatment. However, although the a is have 
been shown to have a negative effect on bone density 
and arthralgia, these effects are manageable, and in-
terventions can be introduced to alleviate symptoms 
and prevent unwanted sequelae. Possible side effects 
should be discussed with the patient, and patient well-
being should be monitored for the duration of treat-
ment. Further, patients with known risk factors such 
as osteopenia, joint pain, or cardiovascular symptoms 
should be identified at the start of treatment, and ap-
propriate interventions should be applied such that 
a i treatment can be continued without worsening of 
symptoms. The goal is to maintain patients on treat-
ment for the allotted length of time while ensuring a 
comfortable quality of life.
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